Cite
Development and characterization of a novel human CD137 agonistic antibody with anti‐tumor activity and a good safety profile in non‐human primates.
MLA
Gao, Yingying, et al. “Development and Characterization of a Novel Human CD137 Agonistic Antibody with Anti‐tumor Activity and a Good Safety Profile in Non‐human Primates.” FEBS Open Bio, vol. 12, no. 12, Dec. 2022, pp. 2166–78. EBSCOhost, https://doi.org/10.1002/2211-5463.13494.
APA
Gao, Y., Yang, T., Liu, H., Song, N., Dai, C., & Ding, Y. (2022). Development and characterization of a novel human CD137 agonistic antibody with anti‐tumor activity and a good safety profile in non‐human primates. FEBS Open Bio, 12(12), 2166–2178. https://doi.org/10.1002/2211-5463.13494
Chicago
Gao, Yingying, Teddy Yang, Hu Liu, Ningning Song, Chaohui Dai, and Yu Ding. 2022. “Development and Characterization of a Novel Human CD137 Agonistic Antibody with Anti‐tumor Activity and a Good Safety Profile in Non‐human Primates.” FEBS Open Bio 12 (12): 2166–78. doi:10.1002/2211-5463.13494.